Cerebrolysin

Product definition

What is Cerebrolysin?

Cerebrolysin is a standardized porcine brain peptide hydrolysate approved in 50+ countries for stroke, TBI, and Alzheimer's — engaging BDNF, GDNF, NGF, and VEGF receptor pathways via its complex peptide mixture.

Cerebrolysin (EVER Neuro Pharma, Austria) is produced by controlled enzymatic hydrolysis of porcine brain protein, yielding a mixture of approximately 85 amino acids and short peptide chains with molecular weights predominantly below 10,000 Da. The mixture is standardized to defined nitrogen content and peptide composition per batch. The active neurotrophic fraction consists of peptides with structural and functional similarity to BDNF, GDNF, NGF, and VEGF fragments — which appear to activate their respective receptor systems without being the intact growth factors themselves. The clinical approval database spans three major neurological indications across multiple regulatory jurisdictions: acute ischemic stroke (IV administration in the acute and subacute phases), traumatic brain injury (IV administration for recovery support), and Alzheimer's disease (cognitive stabilization, documented in multiple RCTs). The Cochrane Collaboration has produced systematic reviews of the Cerebrolysin stroke and dementia clinical trial literature, providing independent meta-analytic assessment of the available evidence. In preclinical research contexts, Cerebrolysin is used as a multi-neurotrophic-factor reference preparation for investigating how simultaneous activation of multiple neurotrophic receptor systems affects neuronal survival, plasticity, and recovery — research questions that cannot be addressed with single neurotrophic factor compounds.

Research context

What does the preclinical literature say about Cerebrolysin?

Cerebrolysin was developed in Austria in the 1940s-50s from the rationale that brain peptide hydrolysates might provide the neurotrophic signals that injured or aging neurons are deprived of. This concept predates the molecular characterization of BDNF, NGF, GDNF, and related factors — the finding that Cerebrolysin's peptide fraction activates these specific receptor systems was characterized retrospectively as the individual neurotrophic factors were identified. The clinical database is the compound's most distinctive feature. Multiple prospective, randomized, controlled trials have been conducted across its three indications in European, Asian, and post-Soviet regulatory contexts. The Cochrane reviews found evidence of functional improvement in stroke patients compared to placebo, with a safety profile consistent with the long regulatory history. The Alzheimer's data showed cognitive stabilization effects in several trials, though effect sizes and methodological consistency are debated in the literature. In translational research, the mechanistic question Cerebrolysin enables is: what is the net effect of activating the full set of neurotrophic receptor systems simultaneously, and does this multi-receptor approach produce different (better or worse) neurological recovery than targeting individual factors? This is a research question that single neurotrophic compounds cannot address.